CN1048498A - The manufacture method of the compositions of treatment immunologic function deficiency disease - Google Patents
The manufacture method of the compositions of treatment immunologic function deficiency disease Download PDFInfo
- Publication number
- CN1048498A CN1048498A CN 89109597 CN89109597A CN1048498A CN 1048498 A CN1048498 A CN 1048498A CN 89109597 CN89109597 CN 89109597 CN 89109597 A CN89109597 A CN 89109597A CN 1048498 A CN1048498 A CN 1048498A
- Authority
- CN
- China
- Prior art keywords
- radix
- compositions
- immunologic function
- treatment
- manufacture method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000036737 immune function Effects 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 16
- 208000027219 Deficiency disease Diseases 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 241000208340 Araliaceae Species 0.000 claims abstract description 5
- 241000756943 Codonopsis Species 0.000 claims abstract description 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims description 5
- 239000010231 banlangen Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 3
- 241000411851 herbal medicine Species 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 18
- 208000032839 leukemia Diseases 0.000 abstract description 13
- 241000700605 Viruses Species 0.000 abstract description 12
- 208000011580 syndromic disease Diseases 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 210000001185 bone marrow Anatomy 0.000 abstract description 6
- 210000004698 lymphocyte Anatomy 0.000 abstract description 5
- 208000032467 Aplastic anaemia Diseases 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 235000009508 confectionery Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 108010074506 Transfer Factor Proteins 0.000 description 2
- 230000001986 anti-endotoxic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241001566735 Archon Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of manufacture method for the treatment of the herbal composite of immunologic function deficiency disease.Compositions is made up of medicines such as Radix Ginseng Rubra, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the Radix Astragali, Os Draconis, Cornu Cervi Degelatinatum, SEMEN COICIS, Herba Hedyotidis Diffusaes.After compositions acted on human body, both capable of killing virus and cancerous cell was repaired and the stimulation bone marrow hematogenesis, can promote lymphocyte transformation again, improves the immunologic function of human body.Said composition can be cured each quasi-leukemia, hematopathys such as aplastic anemia, and be used for treating acquired immune deficiency syndrome (AIDS).Compositions has the property of medicine of even reinforcing-reducing method and heat-clearing and toxic substances removing, and is nontoxic, and it is sweet to distinguish the flavor of, not dry not cool, the prescription balance.
Description
The present invention relates to a kind of manufacture method for the treatment of the herbal composite of immunologic function deficiency disease.
Immunologic function lacks depletion and viral infection is to cause each quasi-leukemia, aplastic anemia, thrombocytopenic purpura, graininess leukopenia or deficiency disease, the root of the ill death of disease such as lupus erythematosus and acquired immune deficiency syndrome (AIDS).With each quasi-leukemia is example, and leukemia virus can make the human deoxyribonucleic acid suddenly change, and upsets gene and genetic code, upsets homergy in the human body and falls ill.It shows as makes the Archon tissue and is unusual diffusivity hypertrophy, the change of the leukocyte amount of having and matter in the blood around, and promptly white blood cell count often increases significantly or reduces, and the juvenile cell appearance is arranged.Thereby the immunologic function major defect occurs, so that because of infection death.And still there are not effective medicine and method for each quasi-leukemia of treatment on the former world.In using embolic chemotherapy, alleviate disease fully though can make some patient, but still can recur in the near future, and chemotherapeutics is when killing leucovirus, also ruined immune function of human body, therefore cause patient's various infection, final owing to infect and immunologic function dies of exhaustion and dies, mortality rate is high.Adopt the bacillus calmette-guerin vaccine intradermal injection for other, or use the transfer factor intramuscular injection, or take levamisole and, also there is no the report of success with increasing trace element treatment etc.
China's traditional Chinese medical science owing to fail to understand the cause of disease, generally all adopts the method for blood circulation promoting and blood stasis dispelling when research and these diseases of treatment, both used Drug therapys such as Semen Persicae, Flos Carthami, Radix Angelicae Sinensis, Rhizoma Curcumae, often causes patient's immunologic function to be lower than more, can not get the effect of satisfaction.
For acquired immune deficiency syndrome (AIDS), it is that a kind of serious human immunity functional defect virus (HIV) infects.When the patient has infected the pathogen of acquired immune deficiency syndrome (AIDS) at first, i.e. after the III type relatives class T cell reversal record virus, because it and T cell have affinity, thereby after invading human body, just invade lymphocyte (especially helper T lymphocyte), in cell, breed, make cell death and can not bring into play immunization.Again because of the minimizing of helper T lymphocyte, suppressor T cell just increases relatively simultaneously, and immunologic function presents inhibitory state, and immunodeficiency takes place thereupon.Human body loses defence capability to multiple pathogen like this, so and pathogenic infection makes immunodeficiency further increase the weight of to cause the vicious cycle of immunodeficiency and infection.In addition, HIV (human immunodeficiency virus) except that containing pathogen, also contains immunosuppressive substance in communication process, and this material can suppress part and systemic immune response again, becomes the accomplice of pathogen invasion, attacks immune system jointly, causes irreversible immunodeficiency.According to the data introduction, treating acquired immune deficiency syndrome (AIDS) now has third kind of interferon of the injection of employing, or uses transfer factor, or injection interleukin II (IL2), or takes thymus transplantation or bone marrow transplantation, in the hope of antiviral and enhancing and reconstruction immunologic function.But because HIV (human immunodeficiency virus) fails to be killed, cause immunologic function to can not get strengthening, depleted gradually on the contrary, and infection is serious further, thereby do not captured so far.
In a word, each quasi-leukemia, aplastic anemia, thrombocytopenic purpura, graininess leukopenia or deficiency disease, lupus erythematosus, scleroderma, hemolytic anemia, and disease such as acquired immune deficiency syndrome (AIDS) all are because the autoimmune defective, anticarcinogen, the contact of immunosuppressant and use, malignant lymphoma or viral infection, the caused immunologic function of reasons such as bacterial infection lacks and depleted patient, the method of not having at present special effective recovery immunologic function all over the world, do not use antiviral yet, the antiendotoxin treatment, thereby these diseases are the incurable diseases of not captured always.
Purpose of the present invention, be at immunologic function deficiency disease and the lethal root of this multiple disease of viral infection, has even reinforcing-reducing method and provide a kind of by what the avirulence Chinese herb medicine combined, the both capable of killing virus and cancerous cell of the heat-clearing and toxic substances removing property of medicine, repair and stimulate bone marrow hematogenesis, can promote lymphocyte transformation again, improve the manufacture method of compositions that the T cell function improves the immunologic function of human body rapidly, to cure aforesaid disease, save patient's life.
The objective of the invention is to realize by following proposal.
The manufacture method of the compositions of treatment immunologic function deficiency disease mixes with the Chinese herbal medicine that comprises following ingredients and ratio:
(1) Radix Ginseng Rubra 1
(2) Radix Codonopsis 0.1-1.5
(3) Rhizoma Atractylodis Macrocephalae 0.1-1.5
(4) Radix Astragali 0.1-1.5
(5) Fructus Lycii 0.1-1.5
(6) Fructus Ligustri Lucidi 0.1-1.5
(7) Semen Cuscutae 0.1-1.5
(8) Pseudobulbus Bletillae (Rhizoma Bletillae) 0.1-1.5
(9) Os Draconis 1-1.5
(10) calculogenesis bone 1-1.5
(11) Cornu Cervi Degelatinatum 1-1.5
(12) Fructus Fici 0.1-0.8
(13) Carapax Trionycis 1.5-2
(14) Radix Asparagi 0.1-1.8
(15) SEMEN COICIS 0.1-1.8
(16) Herba Hedyotidis Diffusae 0.1-3.5
(17) Herba Scutellariae Barbatae 0.1-3.5
(18) Radix Glycyrrhizae 0.2-0.5
(19) Flos Lonicerae 0.1-1.8
(20) Herba Violae 0.1-0.8
(21) Radix Isatidis 0.1-0.8
(22) Folium Isatidis 0.1-0.8
(23) Radix Arnebiae (Radix Lithospermi) 0.1-0.8
(24) Fructus Jujubae 0.2-0.8
The manufacture method of the compositions of treatment immunologic function deficiency disease is to make medicated powder by preparation, weighing, pulverizing, capable more fried patent medicine before waiting to take.Also can be in preparation, carry out after the weighing friedly, be filled in the container then, or make pill, tablet etc.
In the present composition:
Radix Ginseng Rubra has stronger anti-tumor activity, when wherein the concentration of ginsenoside 20 (R) and R6 reaches every milliliter 0.1 microgram, stronger tumoricidal activity is just arranged, when concentration is every milliliter 2 microgram, can press down the people significantly and make body inmature leukemia HL-60 tumor strain early, can make the malignant proliferation leukaemia another mistake that reverses sudden change transfer normal cell to, and can the enhance immunity function.
Radix Codonopsis, the Radix Astragali, careless Fructus Lycii, Fructus Ligustri Lucidi, Semen Cuscutae have the lifting erythrocyte, and erythrocyte can adhere to virus, and virus is lost activity, and increases the effect of immunologic function.
The Rhizoma Atractylodis Macrocephalae has strengthening the spleen and stomach, dries, strengthens the effect of gastrointestinal function and immunologic function.
But Pseudobulbus Bletillae (Rhizoma Bletillae) promoting regeneration of the tissue and arresting bleeding.
Os Draconis has reparation bone marrow, and the effect of hemopoietic raw material is provided.
But Gypsum Fibrosum antiviral, antibiotic.
Cornu Cervi Degelatinatum can improve erythrocyte and platelet.
Fructus Fici can be anticancer.
Carapax Trionycis has enriching yin and nourishing kidney, increases immunologic function and increases proteinic effect.
Radix Asparagi, SEMEN COICIS, Flos Lonicerae, Herba Violae, Radix Isatidis, Folium Isatidis, Radix Arnebiae (Radix Lithospermi) have antiviral, anticancer and the effect of anti AIDS virus and the effect of antiendotoxin and increase immunologic function.
That Herba Hedyotidis Diffusae has is anticancer, antiviral and antimicrobial effect, simultaneously also raise immunity.
Herba Scutellariae Barbatae has antiinflammatory, antiallergic action, antiviral, detoxifcation, blood fat reducing, blood pressure regulation and anticancer effect.
After compositions of the present invention acts on human body, can make the malignant proliferation leukaemia be reversed into normal blood cell, repair stimulate bone marrow hematogenesis, make hemogram, bone marrow normal.Original juvenile cell disappears.Can stimulate the reticuloendothelial system hypertrophy and strengthen the phagocyte vigor; To acute lymphoblastic type granulocyte, the tumor cell of monocyte type and chronic granulocyte type has stronger inhibitory action.Can promote lymphocytic conversion, lymphocyte and leukocytic numerical value are improved, strengthen the function of T cell and improve gamma globulin, promote human body antibody to form, recover immunologic function rapidly, improve life quality.And can both prolong the time-to-live to various malignant tumor patients, and can protect bone marrow to be without prejudice to the tumor patient chemotherapeutic period, do not damage normal cell.
After compositions of the present invention acts on human body, virus had lethal effect, can penetrate blood brain barrier, the reversal procedures that suppresses virus, suppress virus replication, but can kill HIV (human immunodeficiency virus) lymphocyte phagocytic virus, erythrocyte can directly adhere on the leucovirus film, form typical garland, can make virus death such as leukemia.
After compositions of the present invention acts on human body, also have biological regulating action, both can make the hyperfunction function reduction of human body, some function that goes down of human body is risen, make each function of human body be tending towards normalization and balance.
Through clinical verification, use each quasi-leukemia 123 example of combination treatment of the present invention, 5 years survivor's 5 examples, 3 years survivor's 10 examples, three months hemogram of taking medicine recover normal, and the treatment phase is discontented with 3 years person's 108 examples.Other treatment aplastic anemia 90 examples are cured 80 examples.Treatment thrombocytopenic purpura 41 examples are cured 38 examples.Treatment lupus erythematosus 54 examples are cured 50 examples.Treatment graininess leukopenia 2 examples are cured 2 examples.Treatment scleroderma 3 examples are cured 3 examples.Treatment hemolytic anemia 7 examples are cured 7 examples.Acquired immune deficiency syndrome (AIDS) is faced the celebrating checking as yet because of no case.But prove that from above-mentioned theory analysis and healing leukemia compositions of the present invention can be used to treat acquired immune deficiency syndrome (AIDS).Lack because acquired immune deficiency syndrome (AIDS), leukemia all are immunologic functions, only be that virus is different, thereby take different antiviral methods to come into force.
Present composition manufacture method is given an example:
Embodiment 1 embodiment 2 embodiment 3 embodiment 4
(1) Radix Ginseng Rubra 1111
(2) Radix Codonopsis 11 0.1 0.8
(3) Rhizoma Atractylodis Macrocephalae 11 0.1 0.8
(4) Radix Astragali 11 0.1 0.8
(5) Fructus Lycii 11 0.1 0.8
(6) Fructus Ligustri Lucidi 11 0.1 0.8
(7) Semen Cuscutae 11 0.1 0.8
(8) Pseudobulbus Bletillae (Rhizoma Bletillae) 11 0.1 0.8
(9) Os Draconis 1.5 1 1.5 1.2
(10) Gypsum Fibrosum 111 1.4
(11) Cornu Cervi Degelatinatum 111 1.2
(12) Fructus Fici 0.8 0.1 0.8 0.6
(13) Carapax Trionycis 1.5 1.5 1.5 1.8
(14) Radix Asparagi 1.5 0.1 1.5 1.2
(15) SEMEN COICIS 1.5 0.1 1.5 1.2
(16) Herba Hedyotidis Diffusae 3 0.1 3 2.4
(17) Herba Scutellariae Barbatae 3 0.1 3 2.4
(18) Radix Glycyrrhizae 0.3 0.3 0.3 0.24
(19) Flos Lonicerae 0.1 0.1 0.8 0.1
(20) Herba Violae 0.1 0.1 0.8 0.1
(21) Radix Isatidis 0.1 0.1 0.8 0.1
(22) Folium Isatidis 0.1 0.1 0.8 0.1
(23) Radix Arnebiae (Radix Lithospermi) 0.1 0.1 0.8 0.1
(24) Fructus Jujubae 0.6 0.6 0.6 0.4
Claims (1)
1, a kind of manufacture method for the treatment of the compositions of immunologic function deficiency disease is characterized in that compositions can be mixed and made into by the Chinese herbal medicine of following ingredients and ratio:
(1) Radix Ginseng Rubra 1
(2) Radix Codonopsis 0.1-1.5
(3) Rhizoma Atractylodis Macrocephalae 0.1-1.5
(4) Radix Astragali 0.1-1.5
(5) Fructus Lycii 0.1-1.5
(6) Fructus Ligustri Lucidi 0.1-1.5
(7) Semen Cuscutae 0.1-1.5
(8) Pseudobulbus Bletillae (Rhizoma Bletillae) 0.1-1.5
(9) Os Draconis 1-1.5
(10) Gypsum Fibrosum 1-1.5
(11) Cornu Cervi Degelatinatum 1-1.5
(12) Fructus Fici 0.1-0.8
(13) Carapax Trionycis 1.5-2
(14) Radix Asparagi 0.1-1.8
(15) SEMEN COICIS 0.1-1.8
(16) Herba Hedyotidis Diffusae 0.1-3.5
(17) Herba Scutellariae Barbatae 0.1-3.5
(18) Radix Glycyrrhizae 0.2-0.5
(19) Flos Lonicerae 0.1-1.8
(20) Herba Violae 0.1-0.8
(21) Radix Isatidis 0.1-0.8
(22) Folium Isatidis 0.1-0.8
(23) Radix Arnebiae (Radix Lithospermi) 0.1-0.8
(24) Fructus Jujubae 0.2-0.8
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89109597 CN1014584B (en) | 1989-12-30 | 1989-12-30 | Process for prodeucing of composition for curing disease of immune function lack |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 89109597 CN1014584B (en) | 1989-12-30 | 1989-12-30 | Process for prodeucing of composition for curing disease of immune function lack |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1048498A true CN1048498A (en) | 1991-01-16 |
| CN1014584B CN1014584B (en) | 1991-11-06 |
Family
ID=4858081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 89109597 Expired CN1014584B (en) | 1989-12-30 | 1989-12-30 | Process for prodeucing of composition for curing disease of immune function lack |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1014584B (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053362C (en) * | 1995-04-27 | 2000-06-14 | 陶振海 | Baicaoshengshou oral liquor and its preparation |
| CN1054289C (en) * | 1994-07-01 | 2000-07-12 | 柳毅 | Medicine for curing tumour |
| CN1055833C (en) * | 1991-09-27 | 2000-08-30 | 北京医科大学 | Preparation method of "Mei Lu Zhi" Immunity and strengthen nutritious liquid |
| CN1056286C (en) * | 1995-07-26 | 2000-09-13 | 李永康 | Traditional Chinese medicine ointment for AIDS |
| CN1060051C (en) * | 1994-05-09 | 2001-01-03 | 邓庆安 | Anti-cancer compn. and prepn. thereof |
| CN1070707C (en) * | 1997-12-17 | 2001-09-12 | 于化舟 | Traditional Chinese medicine for curing AIDS and its producing method |
| CN1090494C (en) * | 1991-10-12 | 2002-09-11 | 龙孟麟 | Leukemia converted from aplastic anemia |
| CN1094058C (en) * | 1999-06-02 | 2002-11-13 | 湖南医科大学附属湘雅医院 | Tolerant Chinese medicine preparation for treating leukemia |
| CN100463692C (en) * | 2004-06-24 | 2009-02-25 | 邢鹤林 | Bone marrow benefiting capsule for treating anemia |
| CN101391103B (en) * | 2008-07-31 | 2013-07-24 | 张可 | Medicine composition for preventing and treating AIDS viral infection |
| CN103385975A (en) * | 2013-07-01 | 2013-11-13 | 冯子政 | Traditional Chinese medicine for treating thrombocytopenia |
| CN105010862A (en) * | 2015-07-20 | 2015-11-04 | 句容市郭庄镇南河农庄 | A Chinese herbal medicine feed additive for enhancing the immunity of Chinese soft-shelled turtle, its preparation method and application |
| CN105194473A (en) * | 2015-09-15 | 2015-12-30 | 徐辉 | Medicine for treating lupus erythematosus and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055843C (en) * | 1995-03-29 | 2000-08-30 | 周宏波 | Method for prepn. of a medicine for treatment of aplastic anemia |
| CN1052892C (en) * | 1995-06-11 | 2000-05-31 | 陈国才 | Medicine for treating AIDS and its preparing method |
-
1989
- 1989-12-30 CN CN 89109597 patent/CN1014584B/en not_active Expired
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055833C (en) * | 1991-09-27 | 2000-08-30 | 北京医科大学 | Preparation method of "Mei Lu Zhi" Immunity and strengthen nutritious liquid |
| CN1090494C (en) * | 1991-10-12 | 2002-09-11 | 龙孟麟 | Leukemia converted from aplastic anemia |
| CN1060051C (en) * | 1994-05-09 | 2001-01-03 | 邓庆安 | Anti-cancer compn. and prepn. thereof |
| CN1054289C (en) * | 1994-07-01 | 2000-07-12 | 柳毅 | Medicine for curing tumour |
| CN1053362C (en) * | 1995-04-27 | 2000-06-14 | 陶振海 | Baicaoshengshou oral liquor and its preparation |
| CN1056286C (en) * | 1995-07-26 | 2000-09-13 | 李永康 | Traditional Chinese medicine ointment for AIDS |
| CN1070707C (en) * | 1997-12-17 | 2001-09-12 | 于化舟 | Traditional Chinese medicine for curing AIDS and its producing method |
| CN1094058C (en) * | 1999-06-02 | 2002-11-13 | 湖南医科大学附属湘雅医院 | Tolerant Chinese medicine preparation for treating leukemia |
| CN100463692C (en) * | 2004-06-24 | 2009-02-25 | 邢鹤林 | Bone marrow benefiting capsule for treating anemia |
| CN101391103B (en) * | 2008-07-31 | 2013-07-24 | 张可 | Medicine composition for preventing and treating AIDS viral infection |
| CN103385975A (en) * | 2013-07-01 | 2013-11-13 | 冯子政 | Traditional Chinese medicine for treating thrombocytopenia |
| CN105010862A (en) * | 2015-07-20 | 2015-11-04 | 句容市郭庄镇南河农庄 | A Chinese herbal medicine feed additive for enhancing the immunity of Chinese soft-shelled turtle, its preparation method and application |
| CN105194473A (en) * | 2015-09-15 | 2015-12-30 | 徐辉 | Medicine for treating lupus erythematosus and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1014584B (en) | 1991-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1048498A (en) | The manufacture method of the compositions of treatment immunologic function deficiency disease | |
| CN101040924B (en) | Chinese traditional medicine for treating fowl coccidiosis and the preparing method thereof | |
| CN1539458A (en) | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN1686502A (en) | Medicine for fortifying human body immune function | |
| CN1047530C (en) | Efficient disinfectant for prawn and its preparing process | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1116049C (en) | Traditional Chinese medicine for curing non-gonococcal urethritis | |
| CN1806834A (en) | Chinese medicine for treating AIDS | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN1116890C (en) | Medicine for treating hepatitis B | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1059590C (en) | Medicine for blood generation and preparing method | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1130529A (en) | Aizikangfuning-Chinese patent drug for treating AIDS and preparing process thereof | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN1150016C (en) | Medicine for treating fever caused by lupus erythematosus and other immunological disease | |
| CN1150914C (en) | Injection solution for resisting virus, promoting immunity and increasing leucocyte and preparation method thereof | |
| CN1253195C (en) | Anti-age capsule of traditional Chinese medicine and preparation method | |
| CN1352966A (en) | Medicine for treating tracheitis and asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C13 | Decision | ||
| GR02 | Examined patent application | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |